

Corporate Credit Rating

Health Industry [Eye Care Hospital Group]

dünyagöz		Long Term	Short Term	
International	Foreign Currency	BB+	B	
	Local Currency	BBB-	A-3	
	Outlook	FC	Stable	Stable
		LC	Stable	Stable
National	Local Rating	BBB-(Trk)	A-3(Trk)	
	Outlook	Stable	Stable	
Sponsor Support		2	-	
Stand Alone		B	-	
Sovereign*	Foreign Currency	BBB-	-	
	Local Currency	BBB-	-	
	Outlook	FC	Stable	-
		LC	Stable	-

*Affirmed by Japan Credit Rating Agency, JCR on July 11, 2014

Analysts: Zeki M. ÇOKTAN / +90 212 352 56 73

zekic@jcrer.com.tr

Orkun İNAN / +90 212 352 56 73

orkuni@jcrer.com.tr

Dünya Göz Hastanesi Sanayi ve Ticaret Anonim Şirketi					
Financial Data	2013*	2012*	2011*	2010*	2009*
Total Assets (000 USD)	134,188	117,910	98,390	101,204	107,970
Total Assets (000 TRY)	285,874	209,596	185,849	155,611	160,583
Equity (000 TRY)	79,661	20,519	18,421	22,194	4,166
Net Profit (000 TRY)	9,959	2,501	-3,439	383	-16,400
Sales (000 TRY)	204,084	162,305	138,449	110,558	83,196
Net Profit Margin (%)	4.88	1.54	-2.48	0.35	-19.71
ROAA (%)	5.37	1.28	-1.53	-5.37	n.a
ROAE (%)	26.54	13	-12.87	-37.65	n.a
Equity / Total Assets (%)	27.87	9.79	9.91	14.26	2.59
Net Working Capital / T. Assets (%)	-33.74	-54.18	-36.6	-32	-36.03
Debt Ratio (%)	72.13	90.21	90.09	85.74	97.41
Asset Growth Rate (%)	36.39	12.78	19.43	51.76	n.a

*End of the year


Company Overview

Dünya Göz Hastanesi Sanayi ve Ticaret Anonim Şirketi and Its Subsidiaries (hereafter, the Group, the Company or Dünya Göz'), with roots dating back to 1995 with the founding of Levent Sağlık Hizmetleri Sanayi ve Ticaret A.Ş. in Istanbul, changed its title in 2004 to DünyaGöz Hastanesi as a first private eye care hospital in the healthcare sector. The group, through its 3 subsidiaries, is one of the largest and most prominent private eye care hospital groups in Turkey.

Dünya Göz Hastanesi and its subsidiaries carry out its operations with a labour force of 1,272 in an operational area of 82,900 square meters as of December, 2013. Its hospital benefits from its strategic location, which currently provides services in miscellaneous cities together with 14 hospitals in Turkey's 8 cities, 1 in Germany, England, Holland and Belgium, respectively.

Dünya Göz Hastanesi Group has been awarded the Joint Commission International (JCI) Accreditation Certificate that demonstrates compliance with International Quality Standards. Dünyagöz continues to expand its geographic footprint by growing its primary care network thanks to strong business performance and improved brand quality.

The Company's main controlling shareholder was Mr. Eray KAPICIOĞLU (55.80%) as of FYE2013.



Strengths

- Competitive strength derived via benefiting from the first-mover advantage (FMA) and high customer confidence,
- New hospitals enhancing its already diversified network
- Positive outlooks in most of the healthcare sector wherein the Group has had operations,
- Shift in the number of patients seeking treatment from the government sector to the private sector,
- Easing liquidity management through planned bond issue,
- Enhancement of group wide operational procedures and managerial reporting through initiation of IT projects,
- Population growth, urbanization, young demographic and the rise in per capita income providing opportunities for growth and market expansion regarding healthcare spending,

Constraints

- Despite an improvement, a low profit margin due to high cost of sales and tougher competition leading to a weaker revenue environment,
- Low level of financial expenses coverage ability exerting huge pressure on the Group's profit generation,
- Escalating pressure in the markets through persistency risk of the social unrest and political turmoil in the region,
- Reversal of flow of funds from emerging markets given the concerns over US quantitative easing,
- Ongoing corrosion in liquidity ratios over the reviewed period,
- Negative net working capital over the reviewed period despite displayed improvement,

Publication Date: July 25, 2014

"Global Knowledge supported by Local Experience"